-continued



wherein W is an amino acid selected from the group consisting of Asp, Cys, Ser, Thr, and Lys.

2. The conjugate of claim **1** wherein the conjugate has a folate receptor relative affinity of about 0.1 or greater compared to folic acid.

3. The conjugate of claim **1** wherein the conjugate has a folate receptor relative affinity of about 0.2 or greater compared to folic acid.

4. The conjugate of claim **1** wherein the conjugate has a folate receptor relative affinity of about 0.5 or greater compared to folic acid.

5-8. (canceled)

9. The conjugate of claim **1**, wherein m is 1 or 2.

10. The conjugate of claim **1**, wherein m is 1.

11. The conjugate of claim **1**, wherein the linker further comprises at least one releasable linker that is not a disulfide.

12. The conjugate of claim **1**, wherein the linker further comprises at least two releasable linkers.

13. The conjugate of claim **12**, wherein at least one releasable linker that is not a disulfide.

14-19. (canceled)

20. The conjugate of claim **1** wherein at least one D is selected form the group consisting of vinca alkaloids, tubulysins, mitomycins, and epothilones.

21. A pharmaceutical composition comprising the conjugate of claim **1**, and one or more carriers, excipients, diluents, and combinations thereof.

22. A method for treating a pathogenic population of cells in a patient, the method comprising administering an effective amount of the conjugate of claim **1**, or a composition thereof comprising one or more carriers, excipients, diluents, and combinations thereof, to the patient.

23. The method of claim **22**, wherein the pathogenic population of cells is a cancer.

24. The method of claim **22**, wherein the pathogenic cells over-express folate receptors.

25. The method of claim **22**, wherein the conjugate binds to a folate receptor on the cancer cell and upon binding is internalized into the cancer cell.

26. A targeted delivery conjugate of the formula ALD_m wherein A is an antifolate; L is a linker comprising at least one releasable linker; m is 1 to about 3; and each D is an independently selected drug, wherein the antifolate is selected from the group consisting of:



wherein

(a) X is N or CH;

(b) Y is NH_2, H, or CH_3;

(c) R^1 is H, CH_3, or CHO;

(d) Z is OH or OCH_3;

(e) R^2 is H or CH_3;

(f) B is NH, NCH_3, or CH_2;

(g) R^3 is CH_2OH or CH_3; and

(h) W is an amino acid selected from the group consisting of Asp, Cys, Ser, Thr, and Lys.

27. The conjugate of claim **26** wherein the antifolate is selected from the group consisting of: